Publications by authors named "M Reig"
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression commonly occurs. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity.
View Article and Find Full Text PDFArticle Synopsis
- Metabolic liver disease is increasingly linked to hepatocellular carcinoma (HCC), but the molecular mechanisms remain poorly understood; this study focuses on DNA methylation's role in HCC associated with metabolic issues.
- The research involved 272 HCC patients and 316 control subjects, revealing 55 DNA methylation markers that effectively distinguished HCC cases from controls, achieving an AUC of 0.79 for accuracy.
- Combining these markers with demographic data improved sensitivity and specificity for identifying patients at risk for metabolic HCC.
Objective: To develop a domain-specific large language model (LLM) for LI-RADS v2018 categorization of hepatic observations based on free-text descriptions extracted from MRI reports.
Material And Methods: This retrospective study included 291 small liver observations, divided into training (n = 141), validation (n = 30), and test (n = 120) datasets. Of these, 120 were fictitious, and 171 were extracted from 175 MRI reports from a single institution.
Article Synopsis
- This study examines how early clinical hepatic decompensation (CHD) affects the overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC) who are receiving systemic treatments like Atezolizumab plus Bevacizumab or Sorafenib.
- Researchers analyzed data from the IMbrave150 trial and found that patients experiencing early CHD had a significantly higher risk of mortality, indicating a poor prognosis.
- The study identifies specific factors (like ALBI grade, INR levels, and macrovascular invasion) that put patients at a greater risk for CHD, suggesting that these could be useful in future clinical trials to better assess patient outcomes.
Article Synopsis
- Recent advancements in understanding liver cancer (hepatocarcinogenesis) have led to increased interest in rare primary liver cancers (PLCs) like combined hepatocellular-cholangiocarcinoma, fibrolamellar carcinoma, and hepatic epithelioid hemangioendothelioma.
- An international panel of experts has compiled information on the causes, diagnosis, and treatment of these rare PLCs.
- While clinical trials for some of these cancers are in progress, there's a clear need for more research and collaboration across nations to improve outcomes.